Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants

Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 237(2022) vom: 15. Apr., Seite 108981
1. Verfasser: Gupta, Divya (VerfasserIn)
Weitere Verfasser: Ahmed, Farhan, Tandel, Dixit, Parthasarathy, Haripriya, Vedagiri, Dhiviya, Sah, Vishal, Krishna Mohan, B, Khan, Rafiq Ahmad, Kondiparthi, Chiranjeevi, Savari, Prabhudas, Jain, Sandesh, Reddy, Shashikala, Kumar, Jerald Mahesh, Khan, Nooruddin, Harshan, Krishnan Harinivas
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antisera COVID-19 F(ab’)(2) Passive immunotherapy SARS-CoV-2 Virus neutralization Antibodies, Neutralizing Antibodies, Viral mehr... Immunoglobulin Fab Fragments Immunoglobulin Fragments
LEADER 01000caa a22002652c 4500
001 NLM338367004
003 DE-627
005 20250303043232.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.108981  |2 doi 
028 5 2 |a pubmed25n1127.xml 
035 |a (DE-627)NLM338367004 
035 |a (NLM)35306171 
035 |a (PII)S1521-6616(22)00062-6 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Gupta, Divya  |e verfasserin  |4 aut 
245 1 0 |a Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.04.2022 
500 |a Date Revised 03.01.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 Elsevier Inc. All rights reserved. 
520 |a Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab')2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab')2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab')2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab')2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab')2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Antisera 
650 4 |a COVID-19 
650 4 |a F(ab’)(2) 
650 4 |a Passive immunotherapy 
650 4 |a SARS-CoV-2 
650 4 |a Virus neutralization 
650 7 |a Antibodies, Neutralizing  |2 NLM 
650 7 |a Antibodies, Viral  |2 NLM 
650 7 |a Immunoglobulin Fab Fragments  |2 NLM 
650 7 |a Immunoglobulin Fragments  |2 NLM 
700 1 |a Ahmed, Farhan  |e verfasserin  |4 aut 
700 1 |a Tandel, Dixit  |e verfasserin  |4 aut 
700 1 |a Parthasarathy, Haripriya  |e verfasserin  |4 aut 
700 1 |a Vedagiri, Dhiviya  |e verfasserin  |4 aut 
700 1 |a Sah, Vishal  |e verfasserin  |4 aut 
700 1 |a Krishna Mohan, B  |e verfasserin  |4 aut 
700 1 |a Khan, Rafiq Ahmad  |e verfasserin  |4 aut 
700 1 |a Kondiparthi, Chiranjeevi  |e verfasserin  |4 aut 
700 1 |a Savari, Prabhudas  |e verfasserin  |4 aut 
700 1 |a Jain, Sandesh  |e verfasserin  |4 aut 
700 1 |a Reddy, Shashikala  |e verfasserin  |4 aut 
700 1 |a Kumar, Jerald Mahesh  |e verfasserin  |4 aut 
700 1 |a Khan, Nooruddin  |e verfasserin  |4 aut 
700 1 |a Harshan, Krishnan Harinivas  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 237(2022) vom: 15. Apr., Seite 108981  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:237  |g year:2022  |g day:15  |g month:04  |g pages:108981 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.108981  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 237  |j 2022  |b 15  |c 04  |h 108981